Lytixar

• CAT Number: I007897
• CAS Number: 1166254-80-3
• Molecular Formula: C43H69N11O3
• Molecular Weight: 788.09
• Purity: ≥95%
• Synonyms: Lytixar; LTX-109; LTX 109; LTX109.;(S)-2-amino-5-guanidino-N-((S)-1-(((S)-5-guanidino-1-oxo-1-(phenethylamino)pentan-2-yl)amino)-1-oxo-3-(2,5,7-tri-tert-butyl-1H-indol-3-yl)propan-2-yl)pentanamide
• Target: Fungal
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: (2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
• InChI: InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
• InChIKey: ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
• SMILES: CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C

Lytixar（Cat No.:I007897）is a selective and potent inhibitor of the Janus kinase (JAK) family of proteins, specifically JAK1 and JAK2, used in the treatment of autoimmune diseases. It modulates cytokine signaling pathways, reducing inflammation and immune cell activation. By inhibiting JAK-mediated signaling, Lytixar helps manage conditions like rheumatoid arthritis, psoriatic arthritis, and other inflammatory disorders. This targeted approach provides therapeutic benefits while minimizing systemic side effects. Lytixar is a key player in immunomodulation, promoting improved outcomes in patients with chronic inflammatory diseases.